Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection

Cytomegalovirus Disease Clinical Trial

Official title: Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection

Status Completed

Clinical Trial Summary

The purpose of the study is to assess the incidence and severity of late Cytomegalovirus (CMV) disease, defined as CMV syndrome or tissue invasive disease occurring between 100 and 200 days and after 200 days post-transplant in patients treated with valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant versus valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cytomegalovirus Disease
• Cytomegalovirus Infections

• NCT number: NCT01509404
• Study type: Interventional
• Source: Medical University of South Carolina
• Status: Completed
• Phase: Phase 4
• Start date: November 2011
• Completion date: December 2015